Table 2.
Predictions of public health impact and cost-effectiveness of RTS,S for the 6–9 month three-dose and four-dose immunisation schedules at 15 years of follow-up in regions with a parasite prevalence in 2–10 year olds of 10–65%
| Three-dose schedule | Four-dose schedule | ||
|---|---|---|---|
| Proportion of clinical cases averted in children younger than 5 years | 16·2% (7·3–24·1) | 21·1% (7·9–30·6) | |
| Proportion of deaths averted in children younger than 5 years | 13·8% (5·3–21·4) | 18·0% (6·0–29·1) | |
| Clinical cases averted per 100 000 fully vaccinated children | 93 940 (20 490–126 540) | 116 480 (31 450–160 410) | |
| Deaths averted per 100 000 fully vaccinated children | 394 (127–708) | 484 (189–859) | |
| Incremental benefit* | |||
| Clinical cases | .. | 22% (3 to 49) | |
| Deaths | .. | 31% (−1 to 53) | |
| ICER per clinical case averted (in US$) | |||
| $2 per dose | $13 (7–88) | $10 (6–93) | |
| $5 per dose | $30 (18–211) | $25 (16–222) | |
| $10 per dose | $61 (31–415) | $51 (28–437) | |
| ICER per DALY averted (in US$) | |||
| $2 per dose | $35 (16–112) | $38 (18–97) | |
| $5 per dose | $80 (44–279) | $87 (48–244) | |
| $10 per dose | $147 (90–556) | $154 (99–487) | |
Data are median (range) across the models' medians. ICER=incremental cost-effectiveness ratios.
*
Proportion of additional events averted with four-dose versus three-dose immunisation schedule.